MX2014008454A - Acidos nucleicos de enlace c5a nuevos. - Google Patents

Acidos nucleicos de enlace c5a nuevos.

Info

Publication number
MX2014008454A
MX2014008454A MX2014008454A MX2014008454A MX2014008454A MX 2014008454 A MX2014008454 A MX 2014008454A MX 2014008454 A MX2014008454 A MX 2014008454A MX 2014008454 A MX2014008454 A MX 2014008454A MX 2014008454 A MX2014008454 A MX 2014008454A
Authority
MX
Mexico
Prior art keywords
new
nucleic acids
binding nucleic
nucleic acid
acid molecule
Prior art date
Application number
MX2014008454A
Other languages
English (en)
Other versions
MX362061B (es
Inventor
Kai Höhlig
Axel Vater
Klaus Buchner
Christian Maasch
Sven Klussmann
Original Assignee
Noxxon Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/000089 external-priority patent/WO2012095303A1/en
Application filed by Noxxon Pharma Ag filed Critical Noxxon Pharma Ag
Publication of MX2014008454A publication Critical patent/MX2014008454A/es
Publication of MX362061B publication Critical patent/MX362061B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

La presente invención se refiere a una molécula de ácido nucleico con la capacidad de enlazar a C5a humano, en donde la molécula de ácido nucleico comprende una extensión central de nucleótidos, en donde la extensión central de nucleótidos comprende una secuencia de nucleótido de 5' AUGn1GGUGKUn2n3RGGGHUGUKGGGn4Gn5CGACGCA 3' [SEQ ID NO: 61], en donde n1 es U o dU, n2 es G o dG, n3 es A o dA, n4 es U o dU,n5 es U o dU y G, A , U , C ,H, K y R son ribonucleótidos, y dU, dG y dA son 2'-desoxirribonucleótidos.
MX2014008454A 2012-01-10 2013-01-10 Ácidos nucleicos de enlace c5a nuevos. MX362061B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12000106 2012-01-10
PCT/EP2012/000089 WO2012095303A1 (en) 2011-01-10 2012-01-10 Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
EP12006960 2012-10-08
PCT/EP2013/000056 WO2013104540A1 (en) 2012-01-10 2013-01-10 New c5a binding nucleic acids

Publications (2)

Publication Number Publication Date
MX2014008454A true MX2014008454A (es) 2015-02-05
MX362061B MX362061B (es) 2019-01-07

Family

ID=48781063

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014008454A MX362061B (es) 2012-01-10 2013-01-10 Ácidos nucleicos de enlace c5a nuevos.

Country Status (19)

Country Link
US (3) US9518265B2 (es)
EP (1) EP2802660B1 (es)
JP (1) JP6415327B2 (es)
KR (1) KR102034203B1 (es)
CN (1) CN104145018B (es)
AU (2) AU2013209131A1 (es)
BR (1) BR112014016877B1 (es)
CA (1) CA2860806C (es)
DK (1) DK2802660T3 (es)
ES (1) ES2786007T3 (es)
HK (1) HK1198371A1 (es)
IL (1) IL233516B (es)
IN (1) IN2014DN05665A (es)
MX (1) MX362061B (es)
PL (1) PL2802660T3 (es)
PT (1) PT2802660T (es)
RU (1) RU2645261C2 (es)
SG (2) SG11201403771SA (es)
WO (1) WO2013104540A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015066027A2 (en) 2013-10-28 2015-05-07 Dots Devices, Inc. Allergen detection
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
US11172873B2 (en) 2018-05-17 2021-11-16 The Procter & Gamble Company Systems and methods for hair analysis
JP7140848B2 (ja) 2018-05-17 2022-09-21 ザ プロクター アンド ギャンブル カンパニー 毛髪被覆率分析のためのシステム及び方法
EP3586865A1 (en) * 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
EP3814504A1 (en) 2018-06-29 2021-05-05 The Procter & Gamble Company Aptamers for personal care applications
JP2022512969A (ja) * 2018-11-12 2022-02-07 アプタリオン バイオテック エージー Ｃｘｃｌ８結合核酸
MX2021012433A (es) 2019-04-16 2021-11-17 Procter & Gamble Aptameros para aplicaciones para el control de olor.
CN113150106B (zh) * 2021-04-26 2022-08-16 华中农业大学 来源于补体成分C5a的抗菌肽及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US6140490A (en) 1996-02-01 2000-10-31 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of complement system proteins
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
EP1306382A1 (de) 2001-10-26 2003-05-02 Noxxon Pharma AG Modifizierte L-Nukleinsäure
ES2346640T4 (es) 2001-10-26 2011-04-26 Noxxon Pharma Ag Ácido l-nucleico modificado.
EP1585817B1 (en) 2002-02-20 2009-09-02 The General Hospital Corporation Conjugates comprising a biodegradable polymer and uses therefor
AU2004230927B9 (en) 2003-04-13 2011-12-01 Enzon Pharmaceuticals, Inc. Polymeric oligonucleotide prodrugs
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
AU2005210142A1 (en) 2004-02-09 2005-08-18 Noxxon Pharma Ag Method for producing conjugates of polysaccharides and polynucleotides
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
WO2005079363A2 (en) 2004-02-12 2005-09-01 Archemix Corporation Aptamer therapeutics useful in the treatment of complement-related disorders
BR122019000248B8 (pt) 2004-03-23 2021-07-27 Complex Biosystems Gmbh reagente de ligador de pró-fármaco de cascata polimérico
CA2585664C (en) 2004-11-05 2014-05-20 The Children's Hospital Of Philadelphia Biodegradable linkers for molecular therapies
CN101107264A (zh) * 2005-01-17 2008-01-16 捷瑞尼股份公司 C5a受体拮抗剂
NZ571791A (en) 2006-03-08 2012-03-30 Archemix Llc Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
CN101534643A (zh) 2006-09-15 2009-09-16 安佐制药股份有限公司 用于递送寡核苷酸的基于位阻酯的生物可降解连接体
WO2008052774A2 (en) 2006-10-31 2008-05-08 Noxxon Pharma Ag Methods for detection of a single- or double-stranded nucleic acid molecule
AU2008303775A1 (en) * 2007-09-24 2009-04-02 Noxxon Pharma Ag C5a binding nucleic acids
JP4642940B2 (ja) 2009-03-11 2011-03-02 オリンパスメディカルシステムズ株式会社 画像処理システム、その外部装置およびその画像処理方法
WO2010108657A2 (en) 2009-03-23 2010-09-30 Noxxon Pharma Ag C5a binding nucleic acids and the use thereof
US8871920B2 (en) 2010-04-21 2014-10-28 Noxxon Pharma Ag Lipid binding nucleic acids
JP2014504865A (ja) * 2011-01-10 2014-02-27 ノクソン ファーマ エージー 標的分子との結合親和性を有する核酸分子およびその生成方法
MX2014004658A (es) 2011-10-21 2015-08-13 Noxxon Pharma Ag Ácidos nucleícos que unen glucagón.
US9163243B2 (en) 2012-01-10 2015-10-20 Noxxon Pharma Ag Nucleic acids specifically binding CGRP

Also Published As

Publication number Publication date
IN2014DN05665A (es) 2015-05-15
IL233516A0 (en) 2014-08-31
BR112014016877A2 (pt) 2019-10-29
US20210163946A1 (en) 2021-06-03
HK1198371A1 (en) 2015-04-10
AU2018271388B2 (en) 2021-03-11
PT2802660T (pt) 2020-04-21
RU2014132708A (ru) 2016-02-27
DK2802660T3 (da) 2020-05-18
CN104145018A (zh) 2014-11-12
EP2802660A1 (en) 2014-11-19
AU2018271388A1 (en) 2018-12-20
JP2015509705A (ja) 2015-04-02
JP6415327B2 (ja) 2018-10-31
US11492625B2 (en) 2022-11-08
US20180223285A1 (en) 2018-08-09
KR20140111703A (ko) 2014-09-19
CN104145018B (zh) 2019-05-10
US10590424B2 (en) 2020-03-17
IL233516B (en) 2018-07-31
US20140364487A1 (en) 2014-12-11
BR112014016877B1 (pt) 2022-03-15
RU2645261C2 (ru) 2018-02-19
US9518265B2 (en) 2016-12-13
MX362061B (es) 2019-01-07
CA2860806C (en) 2020-10-20
PL2802660T3 (pl) 2020-07-27
SG10201605594UA (en) 2016-09-29
ES2786007T3 (es) 2020-10-08
WO2013104540A1 (en) 2013-07-18
CA2860806A1 (en) 2013-07-18
EP2802660B1 (en) 2020-02-19
SG11201403771SA (en) 2014-07-30
KR102034203B1 (ko) 2019-10-18
AU2013209131A1 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
MX362061B (es) Ácidos nucleicos de enlace c5a nuevos.
CY1120685T1 (el) Ρετινοειδες-λιποσωματα για ενισχυση ρυθμισης εκφρασης hsp47
WO2014028429A3 (en) Enzymes and polymerases for the synthesis of rna
UA118014C2 (uk) Спосіб модифікації днк-мішені
WO2014096992A8 (en) Acetyl transferases and their use for producing carotenoids
RS54649B1 (en) NUCLEIC ACID ANTISENS
IN2014DN03463A (es)
NZ631512A (en) Compositions and methods for modulating apolipoprotein (a) expression
WO2011079902A3 (en) Biological inhibitors of ror1 capable of inducing cell death
MX2011003229A (es) Terapia genica con porfobilinogeno desaminasa.
MX2013007678A (es) Moleculas de acido nucleico dirigidas ala pequeña proteina de union de gtp rho1 y que confieren resistencia a las plagas de coleopteros.
NZ607870A (en) Lactococcus crispr-cas sequences
WO2013090457A3 (en) In vivo delivery of oligonucleotides
EA201692359A1 (ru) Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса
IN2012DN00403A (es)
MX2013007286A (es) Construccion de adn inmunomoduladora no codificante.
WO2011056005A3 (ko) 안티센스 가닥에 의한 오프-타겟 효과를 최소화한 신규한 ｓｉＲＮＡ 구조 및 그 용도
AU2014219019A8 (en) Short interfering nucleic acid (siNA) molecules containing a 2' internucleoside linkage
EP2274442A4 (en) CONSENSUS SEQUENCES OF CHIKUNGUNYA VIRUS PROTEINS, NUCLEIC ACID MOLECULES ENCODING SAME, AND COMPOSITIONS AND METHODS OF USE THEREOF
MX2010003109A (es) Acidos nucleicos de enlace c5a.
EA201101627A1 (ru) Рекомбинантные бактерии и их применение для получения этанола
AU2007240448A8 (en) Methods and compositions for expressing negative-sense viral RNA in canine cells
WO2012046084A3 (en) Short rna molecules
NZ700902A (en) Lowering saturated fatty acid content of plant seeds
WO2010107955A3 (en) RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING

Legal Events

Date Code Title Description
FG Grant or registration